Management of Sickle Cell Disease with Hydroxyurea and Antibiotics

Foundation Therapy and Safety

Hydroxyurea has a long-standing safety profile with no increased risk of birth defects, infection, stroke, or neoplasia in long-term follow-up, according to Praxis Medical Insights 1
The American Society of Hematology guidelines discuss combination therapies with hydroxyurea, specifically addressing erythropoiesis-stimulating agents in the context of chronic kidney disease 2, 3, 4

Do not discontinue hydroxyurea when initiating doxycycline for infections or other indications, as recommended by Praxis Medical Insights 1
Hydroxyurea should be taken once daily and continued without interruption unless dose-limiting myelosuppression occurs 1
Complete blood count with reticulocyte count should be monitored every 2-4 weeks during initial dose titration and every 1-3 months once on stable dose 1
The primary concern with hydroxyurea is myelosuppression, which typically resolves within 2 weeks of temporary discontinuation if needed 1

Only discontinue hydroxyurea temporarily if severe bone marrow suppression develops (decreased counts in one or more cell lines) 5
After resolution of toxicity, therapy can be resumed at a lower dose 1

In patients with chronic kidney disease receiving combination therapy with erythropoiesis-stimulating agents, hemoglobin levels should not exceed 10 g/dL to reduce risk of vaso-occlusive complications 1, 5, 6
This threshold applies regardless of concurrent antibiotic use 6